GlassScriptPhysician profile
Laura Doanes
NPI 1558750182
$1,606.33
in general payments reported to CMS, 2019-2025
19 companies · $16.22 in 2025
The $16.22 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $48.02 · 2024: $1,542 · 2025: $16.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,606.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $264.43 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $211.69 | 2024 | |
| Abbvie INC. | $209.95 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $190.45 | 2024 | Airsupra, Farxiga |
| Lilly USA, LLC | $172.80 | 2024 | Mounjaro, Zepbound |
| Braeburn INC. | $96.45 | 2024 | Brixadi |
| Indivior INC. | $78.22 | 2024 | Sublocade |
| Exact Sciences Corporation | $66.90 | 2023-2024 | Cologuard Collection Kit |
| Ardelyx, INC. | $61.64 | 2024 | Ibsrela |
| Janssen Pharmaceuticals, INC | $61.57 | 2024 | Spravato, Xarelto |
| Novo Nordisk INC | $38.44 | 2023-2024 | |
| Gilead Sciences, INC. | $34.33 | 2024 | Descovy |
| Shield Therapeutics INC | $22.16 | 2024 | |
| Corium, LLC | $21.11 | 2024 | Azstarys |
| Tactile Systems Technology INC | $18.06 | 2024 | Flexitouch Plus, Entre Plus |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $16.22 | 2025 | Korlym |
| Phathom Pharmaceuticals, INC. | $15.01 | 2024 | Voquezna |
| Amgen INC. | $14.17 | 2024 | Prolia, Evenity |
| Collegium Pharmaceutical, INC. | $12.73 | 2023 | Belbuca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Doanes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.